Skip to content

Why Subscribe
About Us
Accreditation
Library
Live Events
Sign Up / Login

Why Subscribe
About Us
Accreditation
Library
Live Events
Sign Up / Login

Library

Speciality

Author / Speaker

Title of Presentation

Type of Media

Event

2024 Event

Clear

Displaying 401 - 425 of 2,711

«
1
…
15
16
17
18
19
…
109
»

CNS METS- Evolving Multidisciplinary Tumor Board Conversations Medical Oncology

CNS METS- Evolving Multidisciplinary Tumor Board Conversations Medical Oncology

By: Andrew Seidman, MD

Neoadjuvant Candidacy and Treatment

Neoadjuvant Candidacy and Treatment

By: Anne O’Dea, MD

Post-Op Decision Making

Post-Op Decision Making

By: Anne O’Dea, MD

Immunotherapy in Breast Cancer: Now & The Future

Immunotherapy in Breast Cancer: Now & The Future

By: Avan Armaghani, MD

Breast Cancer – Transgender Construction and Deconstruction

Breast Cancer – Transgender Construction and Deconstruction

By: Bella Avanessian, MD

De-Escalation

By: Beryl McCormick, MD

HER2-Positive Breast Cancer Updates

HER2-Positive Breast Cancer Updates

By: Bora Lim, MD

Controversy in Breast Cancer- Should be pCR Be an Acceptable Endpoint for Approval of New Therapies for Early-Stage Breast Cancer (NO)

Controversy in Breast Cancer- Should be pCR Be an Acceptable Endpoint for Approval of New Therapies for Early-Stage Breast Cancer (NO)

By: Cesar A. Santa-Maria, MD, MSCI

Controversy in Breast Cancer- Should be pCR Be an Acceptable Endpoint for Approval of New Therapies for Early-Stage Breast Cancer (NO)

Controversy in Breast Cancer- Should be pCR Be an Acceptable Endpoint for Approval of New Therapies for Early-Stage Breast Cancer (NO)

By: Cesar A. Santa-Maria, MD, MSCI

Stage 1A – De-Escalation v Escalation

Stage 1A – De-Escalation v Escalation

By: Chau Dang, MD

Metastatic HER2neu Positive Breast Cancer

Metastatic HER2neu Positive Breast Cancer

By: Chau Dang, MD

The Art of Medicine in the Clinic

The Art of Medicine in the Clinic

By: Chelsea Gawryletz, MD

Neoadjuvant and Adjuvant Approaches

Neoadjuvant and Adjuvant Approaches

By: Claudine Isaacs, MD

Immunotherapy for Breast Cancer: When to Use and Future Directions

Immunotherapy for Breast Cancer: When to Use and Future Directions

By: Evanthia Torres, MD, PhD

Immunotherapy for Breast Cancer: Efficacy and Toxicity Considerations

Immunotherapy for Breast Cancer: Efficacy and Toxicity Considerations

By: Heather McArthur, MD, MPH

Immunotherapy for Breast Cancer: Efficacy and Toxicity Considerations

Immunotherapy for Breast Cancer: Efficacy and Toxicity Considerations

By: Heather McArthur, MD, MPH

Localized Breast Cancer Updates

Localized Breast Cancer Updates

By: Helen Chew, MD

HER2 Targeted Therapies: Recent Advances

HER2 Targeted Therapies: Recent Advances

By: Helen Chew, MD, FACP

Cell Cycle and Immune Check Point Inhibitors | Research, Clinic, Patient

Cell Cycle and Immune Check Point Inhibitors | Research, Clinic, Patient

By: Hope Rugo, MD

Antibody Drug Conjugates for HER2 Negative Breast Cancer: A Revolution in Chemotherapy for Breast Cancer

Antibody Drug Conjugates for HER2 Negative Breast Cancer: A Revolution in Chemotherapy for Breast Cancer

By: Hope S. Rugo, MD, FASCO

Antibody Drug Conjugates for HER2 Negative Breast Cancer: A Revolution in Chemotherapy for Breast Cancer

Antibody Drug Conjugates for HER2 Negative Breast Cancer: A Revolution in Chemotherapy for Breast Cancer

By: Hope S. Rugo, MD, FASCO

Maturity of the Patient and evolving treatment options

Maturity of the Patient and evolving treatment options

By: Hyman Muss, MD

ILC, When Non-scary Becomes Scary

ILC, When Non-scary Becomes Scary

By: Jason Aboudi Mouabbi, MD

New Biomarkers in Breast Cancer

New Biomarkers in Breast Cancer

By: Joanne Mortimer, MD, FACP, FASCO

Role of Radiation in breast cancer

Role of Radiation in breast cancer

By: Joe Panoff, MD

«
1
…
15
16
17
18
19
…
109
»

© 2024 MEC Inc. All rights reserved | Digital Marketing by Katapult Marketing

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok